These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7591964)

  • 21. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Mao G; Gao Z; Wang Q
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility of monocytes to lymphokine-activated killer cell lysis: effect of granulocyte-macrophage colony-stimulating factor and interleukin-3.
    Djeu JY; Widen R; Blanchard DK
    Blood; 1989 Apr; 73(5):1264-71. PubMed ID: 2649172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of corticosteroid on lymphokine-activated killer (LAK) activity and the change of membrane antigen phenotype on PBMC after IL2 incubation with reference to the evaluation in vitro].
    Yoshimura A
    Nihon Ika Daigaku Zasshi; 1990 Jun; 57(3):211-21. PubMed ID: 2376610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
    Guo YS; Xing ZL
    Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrapleural administration of interleukin-2 and LAK cells in locally advanced non-small-cell lung cancer. A case report.
    Matteucci P; Tresoldi M; Chiesa G; Tognella S; Citterio G; Fortis C; Besana C; Rugarli C
    Tumori; 1994 Jun; 80(3):246-50. PubMed ID: 8053086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
    Bendall LJ; Kortlepel K; Gottlieb DJ
    Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphokine-activated killer cell regulation of T-cell-mediated immunity to Candida albicans.
    Wei S; Blanchard DK; McMillen S; Djeu JY
    Infect Immun; 1992 Sep; 60(9):3586-95. PubMed ID: 1500166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
    Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
    J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
    Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
    Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
    Tjota A; Zhang YQ; Piedmonte MR; Lee CL
    J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y; Tanaka T; Tanji Y; Fujiwara A; Taguchi T
    Biotherapy; 1994; 8(1):41-50. PubMed ID: 7547080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of recombinant interleukin 1 beta on peripheral blood cells and induction of lymphokine-activated killer activity in patients with urological malignancies].
    Marumo K; Ueno M; Muraki J; Tachibana M; Deguchi N; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1991 Aug; 82(8):1211-7. PubMed ID: 1921014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
    Sone S; Yanagawa H; Nii A; Ozaki T; Ogura T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1434-40. PubMed ID: 1434216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.
    Yeung AW; Pang YK; Tsang YC; Wong SW; Leung JS
    Cancer; 1993 Jun; 71(11):3633-9. PubMed ID: 8387882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients.
    Joshi SS; Miller K; Jackson JD; Warkentin P; Kessinger A
    Cytotherapy; 2000; 2(1):15-24. PubMed ID: 12042051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation of human NK cells and generation of LAK activity.
    Whiteside TL
    Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin.
    Basu S; Sodhi A; Singh SM; Suresh A
    Immunol Lett; 1991 Mar; 27(3):199-204. PubMed ID: 2060971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.